Mirati steps on the gas with KRAS inhibitor, looking to claim second approval behind Amgen's Lumakras
Amgen beat Mirati to the finish line with the first-ever approved KRAS inhibitor back in May. But Mirati’s picking up the pace and says it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
